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INSIGHTS FROM MODEL SYSTEMS
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“As Gregor Samsa awoke one morning from uneasy dreams he found himself
transformed in his bed into a gigantic insect . . .”
[Franz Kafka, The Metamorphosis]
As foreign as an insect’s body felt to Kafka’s Samsa, the
homology of flies and humans is astonishing. Approx-
imately 80% of human genes have a genetic homologue
in the fruit fly, Drosophila melanogaster (Cookson
1997). Although Drosophila has only ∼10,000 genes in
its genome, compared with ∼100,000 genes in a mam-
malian cell, most human genes are duplications and elab-
orations of their insect equivalents (Lundin 1993; Hol-
land et al. 1994; Miklos and Rubin 1996). In fact, not
only individual domains and proteins but entire com-
plexes and multistep pathways are conserved between
fly and man (Artavanis-Tsakonas et al. 1995; Wasser-
man et al. 1995).
Because so many pathways are conserved, a significant
number of genes studied in flies have proved to be hom-
ologues of human oncogenes and tumor suppressors
(Miklos and Rubin 1996). The knowledge that we have
gained from studying these Drosophila genes and the
biological processes in which they participate contrib-
utes to our understanding of the mechanisms of action
of their human counterparts.
Perhaps it is less widely known that Drosophila can
develop tumors and that they display the full range of
characteristics of human cancers. As we describe below,
powerful genetic screens have been designed to identify
genes that are responsible for such neoplastic growths
in flies. When pursued, human homologues of fly tumor
suppressors, and vice versa, have been isolated and have
been shown to be functionally conserved. Thus, Dro-
sophila is an excellent model for studying the molecular
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mechanisms of tumorigenesis and directly contributes to
our understanding of cancer biology.
Identification of Tumor Suppressors in Drosophila:
The Power of Genetic Mosaics
Hereditary tumors were reported in the earliest days
of Drosophila genetics. In 1916, Bridges discovered a
spontaneous lethal mutation that causes homozygous
larvae to develop “black granules” in their bodies. Later,
these granules were characterized by Stark (1918) as
being “melanotic tumors.” When human carcinogens
were examined in Drosophila, they were found to effi-
ciently induce various tumors (Harshbarger and Taylor
1968). Subsequently, the properties of Drosophila tu-
mors caused by a number of genetic lesions were further
analyzed by Gateff and others (Gateff and Schneiderman
1969; Gateff 1978). Many of these tumor-causing le-
sions behave as recessive mutations and therefore are
defined as tumor suppressors (e.g., see Woods and Bry-
ant 1989; Mahoney et al. 1991). Most of these tumor
suppressors were identified because they cause late-larval
lethality in homozygous animals. Phenotypic character-
ization of dead larvae by dissection subsequently re-
vealed occasional overproliferation of internal tissues.
Using this information, systematic screens of collections
of late-larval lethal mutants identified more tumor sup-
pressors (To¨ro¨k et al. 1993).
Many tumor suppressors regulate cell proliferation
and differentiation during early development. Conse-
quently, germ-line mutations in these genes may cause
embryonic lethality in homozygous animals. To circum-
vent this, we have been screening for tumor suppressors
in mosaic flies (Xu et al. 1995; also see fig. 1 and
sidebar). In such screens, populations of heterozygous
embryos are produced from mutagenized parents. A few
somatic cells in each developing heterozygous animal are
then induced to become homozygous for the newly gen-
erated mutation. Mosaic individuals that carry small
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Figure 1 Identification of tumor suppressors in mosaic flies. Al-
though animals that are homozygous for a lethal mutation could die
at an early developmental stage, mosaic flies carrying clones of cells
that are homozygous for the same mutation can live. One can identify
potential tumor suppressors by generating and examining clones of
overproliferated mutant cells in mosaic animals. The genetic consti-
tution of these mosaic flies is similar to the mosaicism of cancer pa-
tients. The middle panel shows that mosaic flies carrying clones of
cells mutant for the lats tumor suppressor develop large tumors in
various tissues; the bottom panel shows the irregular growth and lu-
men-containing structures in a lats tumor section. (The top panel of
this figure is reprinted from the article by Xu et al. [1995, p. 1055]
and is reprinted here with permission from the journal Development
and Company of Biologists Ltd.)
patches of cells mutated for a tumor suppressor are vi-
able, yet the overproliferation mutant phenotype is read-
ily detectable. Once a tumor-carrying fly is identified, the
mutation of interest can be recovered from its hetero-
zygous germ-line cells by mating (Xu and Harrison
1994; also see sidebar). The mosaic nature of these flies
mimics the genetic constitution of human cancer patients
who are chimeric individuals carrying a small number
of cells that are mutant for tumor suppressors or proto-
oncogenes (fig. 1). Such mosaic screens were achieved
because of the construction of special Drosophila chro-
mosomes (Xu and Rubin 1993). The FRT ( FLP recom-
binase target) sequence, which is the recombination tar-
get site of the yeast FLP enzyme, has been inserted near
the centromere of each chromosome arm. When FLP is
induced in developing flies, high frequencies of mitotic
recombination occur between FRT sites on homologous
arms (Golic 1991). Thus, mutant clones can be efficiently
induced for most of the fly genome. Various genetic and
cell markers have also been introduced into these FRT-
carrying chromosomes (Xu and Rubin 1993; Xu et al.
1995). Cosegregation of these markers and the mutation
of interest allows the identification of the clones of mu-
tant cells in both adult and developing tissues (see
sidebar).
Using this mosaic-screen approach, we have identified
several novel genes that, when inactivated, cause dra-
matic overproliferation phenotypes (Xu et al. 1995).
These mutations cause embryonic lethality without ob-
vious morphological defects and thus were not identified
in previous genetic screens that examined homozygous
mutants. The identified overproliferation mutations can
be classified into two different groups. Mutations in the
first group cause mutant cells to overproliferate and to
form unpatterned tumorous tissues, whereas the second
type of mutations induce patterned outgrowth structures
in addition to tumorous tissues. Our genetic and mo-
lecular characterization suggests that the first type of
mutations affect components that are involved in the
regulation of the cell cycle, whereas the second type of
mutations perturb developmental signals regulating pat-
tern formation (W. Tao, M. A. R. St. John, S. Zhang,
R. A. Stewart, and T. Xu, unpublished data).
The Drosophila large tumor suppressor gene (lats
[which is also known as warts]) is an example of the
first group of mutations and has been extensively char-
acterized (Justice et al. 1995; Xu et al. 1995). Molecular
characterization of lats predicts its gene product to be
a novel Ser/Thr protein kinase with a putative SH3-bind-
ing site. Somatic cells that are mutant for lats undergo
extensive proliferation and form large tumors in many
tissues of mosaic animals (fig. 1). Animals that are ho-
mozygous for the various lats alleles display a wide range
of developmental defects, including embryonic lethality,
overproliferation of both neural and epidermal tissues,
rough eyes, and sterility.
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FLPing out tumor-suppressor genes
Working with Drosophila permits us to generate and analyze
chimeric animals with distinct and defined genotypes in differ-
ent tissues. The FLP/FRT site-specific recombination system
from yeast has been introduced into the fly genome to efficiently
generate genetic mosaics. The FRT sequence is integrated into
chromosome arms proximal to the centromeres (Xu and Rubin
1993). Expression of FLP recombinase is under the control of
the inducible-heat-shock promoter (Golic and Lindquist 1989).
By inducing heat shock, we can activate mitotic recombination
at any point during fly development. In a heterozygous cell,
FLP induces mitotic recombination between FRT sites on ho-
mologous chromosome arms. Segregation of recombinant chro-
mosomes at mitosis can produce a cell homozygous for the part
of the chromosome distal to the FRT sites, where a mutant
tumor-suppressor gene, such as lats, may reside. The cosegre-
gation of p-MYC (pM), a cell marker, on the same arm allows
the identification of the mutant cells and its descendants (white
cells). The complementary recombination product is homozy-
gous wild type and carries two copies of the pM marker.
This micrograph shows a section of a mosaic larval eye disk
in which recombination was induced. The disk was stained to
allow visualization of the pM cell marker. A clone of nonflu-
orescent cells that lack the pM marker (arrow) is accompanied
by a brightly stained twin-spot clone (arrowhead), which ex-
presses the pM protein at a higher level than the heterozygous
background cells. Clones lacking the marker are homozygous
for a mutation in a tumor-suppressor gene and, as such, are
destined to overproliferate to form large tumors. Mosaic ani-
mals are instrumental for the identification of tumor-suppressor
genes such as lats (Xu et al. 1995), whose functions are con-
served from flies to humans. (The bottom of this figure is from
the article by Xu and Rubin [1993, p. 1226] and is reprinted
here with permission from the journal Development and Com-
pany of Biologists Ltd.)
Understanding Human Cancer in a Fly?
Drosophila neoplasms display a range of character-
istics. The assessments used to define neoplasia in Dro-
sophila are quite similar to those used by clinical tumor
pathologists: (1) in situ cell overproliferation, (2) altered
cell morphology, (3) loss or decrease of differentiation
capacity, (4) in situ invasiveness, and (5) transplanta-
bility (Mechler and Strand 1990). The two last char-
acteristics distinguish malignant from benign neoplasms.
After transplantation, malignant neoplasms grow ag-
gressively and kill the host, whereas benign neoplasms
are unable to proliferate. As in human cancer, benign
neoplasms remain confined to the tissue of origin.
Tumors that result from inactivation of lats display
many features of human neoplasms. The lats mutant
cells grow aggressively, and a single mutant cell can de-
velop into a tumor that is one-fifth the size of the animal.
These tumors are highly irregular in shape and size and
are often poorly differentiated. Sections of these tumors
reveal that they harbor lumen-containing structures,
which is reminiscent of aggressive angiogenesis in human
tumors (Xu et al. 1995; also see fig. 1).
Malignant growth has been well documented in fly
tumors derived from lgl mutants (Woodhouse et al.
1994). The flies with the lgl mutation do not survive
beyond the larval stage, but, amazingly, when the larval
brain tumors are transplanted into a normal adult fly,
the tumors invade and spread to distant organs. Inter-
estingly, examination of specific proteins (e.g., type IV
collagenase) that are differentially expressed in mam-
malian metastatic tumors have revealed that homolo-
gous proteins are also expressed in lgl tumors (Wood-
house et al. 1994). These data strongly suggest that
metastasis of Drosophila tumor cells is similar to that
of human tumors.
Moreover, evidence has started to emerge that some
human homologues of fly tumor suppressors may play
roles similar to those in their fly counterparts. In the case
of lats, its human homologue has been isolated. The
human lats gene is able to suppress tumorigenesis and
to rescue all developmental defects in lats mutants (W.
Tao, M. A. R. St. John, S. Zhang, R. A. Stewart, and
T. Xu, unpublished data). Such data provide strong ev-
idence that lats is conserved from fly to human, indi-
cating that we can use the fly to understand many aspects
of human cancer.
Tip of the Iceberg
In addition to recessive overproliferation lesions, gain-
of-function mutations that lead to tumor formation have
also been identified in Drosophila. For example, Tu-
morous-lethal (hoptum-l), a dominant mutation in the
Drosophila Hopscotch/Janus kinase gene, causes he-
matopoietic overproliferation (Harrison et al. 1995; Luo
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et al. 1995). Similar to their human counterparts, acti-
vation mutations of the fly ras and Notch genes cause
overproliferation defects (G. Rubin and S. Artavanis-
Tsakonas, personal communication). In each case, the
entire signal-transduction pathway in which the gene
participates is conserved from fly to human (Artavanis-
Tsakonas et al. 1995; Wasserman et al. 1995).
Because the molecular pathways that have been stud-
ied are well conserved, other essential pathways for reg-
ulation of cell proliferation in humans should also be
present in flies. The wealth of knowledge about Dro-
sophila developmental biology, as well as experimental
tools such as genetic modifier screens for assembling
genes into pathways, make the fly one of the best systems
for dissection of functions for human cancer genes. The
characterization of RBF, the Drosophila homologue of
the retinoblastoma-susceptibility gene, is one such ex-
ample (Du et al. 1996). Once again, the molecules of
the Rb pathway and their biochemical properties are
conserved in flies. RBF regulates cell proliferation by
modulation of gene expression, through binding of the
Drosophila E2F/DP complex (Dynlacht et al. 1994; Du
et al. 1996). However, it is clear that the flyRBF pathway
is much simpler than the human one. Although one RBF
and two E2F have been identified in Drosophila, three
Rb-family molecules (Rb, p107, and p130) and at least
five E2F members have been found in mammals (Wein-
berg 1995). Characterization of the Enhancer and Sup-
pressor modifier genes of RBF and dE2F will soon pro-
vide new details about the Rb pathway.
The mosaic screens used to identify tumor suppressors
in Drosophila are by no means saturated. Future genetic
screens will identify more and perhaps most of the neg-
ative regulators of cell proliferation. On the other hand,
as the human- and fly-genome projects progress, many
more fly homologues of human cancer-causing genes will
be revealed. Given the extraordinary conservation of the
molecular pathways that exists between flies and hu-
mans, Drosophila is destined to become one of the hot-
test models for cancer research.
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